How i do it: Surgical management of gastrointestinal stromal tumors

Journal of Gastrointestinal Surgery

Volumn 12, Issue 9, 2008, Pages 1592-1599

  Raut, Chandrajit P ^a,b   Ashley, Stanley W ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant therapy; Gastrointestinal stromal tumor; Metastases; Sarcoma; Surgery

Indexed keywords

PROTEIN KINASE INHIBITOR;

ABDOMINAL SURGERY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; CANCER INVASION; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; LAPAROSCOPY; LAPAROTOMY; MALE; METHODOLOGY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; LAPAROSCOPY; LAPAROTOMY; MAGNETIC RESONANCE IMAGING; MALE; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROTEIN KINASE INHIBITORS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 49749090472     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-008-0501-3     Document Type: Article

References (26)

1. Gayed I, Vu T, Iyer R, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004;45(1):17-21.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23(2):70-83.
3. Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003;6(1):39-48.
4. Otani Y, Furukawa T, Yoshida M, et al. Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery 2006;139(4):484-492.
5. Novitsky YW, Kercher KW, Sing RF, Heniford BT. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg 2006;243(6):738-45. discussion 745-747.
6. Agaimy A, Wunsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007;31(1):113-120.
7. Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006;37(12):1527- 1535.
8. Davila RE, Faigel DO. GI stromal tumors. Gastrointest Endosc 2003;58(1):80-88.
9. Heinrich MC, Corless CL. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy. J Surg Oncol 2005;90(3):195-207. discussion 207.
10. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007;5(Suppl 2):S1-29. quiz S30.
11. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001;8(1):50-59.
12. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231(1):51-58.
13. Pierie JP, Choudry U, Muzikansky A, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001;136(4):383-389.
14. DeMatteo R, Owzar K, Maki R, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. Proc Am Soc Clin Oncol 2007:Abstract No 10079.
15. Bauer S, Hartmann JT, de Wit M, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 2005;117(2):316-325.
16. Scaife CL, Hunt KK, Patel SR, et al. Is there a role for surgery in patients with "unresectable" cKIT + gastrointestinal stromal tumors treated with imatinib mesylate. Am J Surg 2003;186(6):665-669.
17. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364(9440):1127-1134.
18. DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007;245(3):347-352.
19. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24(15):2325-2331.
20. Heinrich MC, Corless CL, Liegl B, et al. Mechanisms of sunitinib malate resistance in gastrointestinal stromal tumors. Proc Am Soc Clin Oncol 2007;25(18S):10006. (Abst).
21. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007;14:14-24.
22. Bonvalot S, Eldweny H, Pechoux CL, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006;13(12):1596-1603.
23. Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007;245(3):341-346.
24. Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006;93(4):304-311.
25. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007;25(9):1107-1113.
26. van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer 2005;104(9):1781-1788.